Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response

Molecular Therapy

Volumn 20, Issue 11, 2012, Pages 2143-2152

  Oh, Joo Youn ^a,b   Lee, Ryang Hwa ^a   Yu, Ji Min ^a   Ko, Jung Hwa ^b   Lee, Hyun Ju ^b   Ko, Ah Young ^b   Roddy, Gavin W ^a   Prockop, Darwin J ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA STIMULATED GENE 6 PROTEIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA STIMULATED GENE 6 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CORNEA TRANSPLANTATION; CORNEAL GRAFT REJECTION; DENDRITIC CELL; ENGRAFTMENT; GENE EXPRESSION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; LUNG; LYMPH NODE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; POSTOPERATIVE INFLAMMATION;

EID: 84869080677     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.165     Document Type: Article

References (32)

1. Hoogduijn, MJ, Popp, FC, Grohnert, A, Crop, MJ, van Rhijn, M, Rowshani, AT et al.; MISOT Study Group. (2010). Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 90: 124-126.
2. Le Blanc, K, Frassoni, F, Ball, L, Locatelli, F, Roelofs, H, Lewis, I et al.; Developmental Committee of the European Group for Blood and Marrow Transplantation. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versushost disease: A phase II study. Lancet 371: 1579-1586. (Pubitemid 351626841)
3. English, K, French, A and Wood, KJ (2010). Mesenchymal stromal cells: Facilitators of successful transplantation? Cell Stem Cell 7: 431-442.
4. Popp, FC, Eggenhofer, E, Renner, P, Geissler, EK, Piso, P, Schlitt, HJ et al. (2009). Mesenchymal stem cells can affect solid organ allograft survival. Transplantation 87(9 Suppl): S57-S62.
5. Singer, NG and Caplan, AI (2011). Mesenchymal stem cells: Mechanisms of inflammation. Annu Rev Pathol 6: 457-478.
6. Uccelli, A, Moretta, L and Pistoia, V (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726-736.
7. Forrester, JV, Xu, H, Kuffova, L, Dick, AD and McMenamin, PG (2010). Dendritic cell physiology and function in the eye. Immunol Rev 234: 282-304.
8. Catron, DM, Rusch, LK, Hataye, J, Itano, AA and Jenkins, MK (2006). CD4+ T cells that enter thedraining lymph nodes after antigen injection participate in the primary response andbecome central-memory cells. J Exp Med 203: 1045-1054.
9. Kuffova, L, Lumsden, L, Vesela, V, Taylor, JA, Filipec, M, Holan, V et al. (2001). Kinetics of leukocyte and myeloid cell traffic in the murine corneal allograft response. Transplantation 72: 1292-1298. (Pubitemid 33026611)
10. Milner, CM, Higman, VA and Day, AJ (2006). TSG-6: A pluripotent inflammatory mediator? Biochem Soc Trans 34(Pt 3): 446-450. (Pubitemid 43954008)
11. Wisniewski, HG and Vilcek, J (2004). Cytokine-induced gene expression at the crossroads of innate immunity, inflammation and fertility: TSG-6 and PTX3/TSG-14. Cytokine Growth Factor Rev 15: 129-146. (Pubitemid 38521249)
12. Choi, H, Lee, RH, Bazhanov, N, Oh, JY and Prockop, DJ (2011). Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-?B signaling in resident macrophages. Blood 118: 330-338.
13. Oh, JY, Choi, H, Lee, RH, Roddy, GW, Ylostalo, JH, Wawrousek, E et al. (2012). Identification of the HSPB4/TLR2/NF-?B axis in macrophage as a therapeutic target for sterile inflammation of the cornea. EMBO Mol Med 4: 435-448.
14. Oh, JY, Roddy, GW, Choi, H, Lee, RH, Ylostalo, JH, Rosa, RH Jr et al. (2010). Antiinflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci USA 107: 16875-16880.
15. Choy, JC (2010). Granzymes and perforin in solid organ transplant rejection. Cell Death Differ 17: 567-576.
16. Hamrah, P, Huq, SO, Zhang, Q and Dana, MR (2003). Corneal immunity is mediated by heterogenous population of antigen-presenting cells. J Leukocyte Biol 74: 172-178. (Pubitemid 38040413)
17. Dana, MR (2004). Corneal antigen-presenting cells: Diversity, plasticity, and disguise: The Cogan lecture. Invest Ophthalmol Vis Sci 45: 722-7; 721. (Pubitemid 38868363)
18. Dana, R (2007). Comparison of topical interleukin-1 vs tumor necrosis factoralpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 105: 330-343.
19. Kuffova, L, Netukova, M, Duncan, L, Porter, A, Stockinger, B and Forrester, JV (2008). Cross presentation of antigen on MHC class II via the draining lymph node after corneal transplantation in mice. J Immunol 180: 1353-1361.
20. Roddy, GW, Oh, JY, Lee, RH, Bartosh, TJ, Ylostalo, J, Coble, K et al. (2011). Action at a distance: Systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-A stimulated gene/protein 6. Stem Cells 29: 1572-1579.
21. Lee, RH, Pulin, AA, Seo, MJ, Kota, DJ, Ylostalo, J, Larson, BL et al. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5: 54-63.
22. Lee, RH, Oh, JY, Choi, H and Bazhanov, N (2011). Therapeutic factors secreted by mesenchymal stromal cells and tissue repair. J Cell Biochem 112: 3073-3078.
23. Prockop, DJ, Kota, DJ, Bazhanov, N and Reger, RL (2010). Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). J Cell Mol Med 14: 2190-2199.
24. Uccelli, A and Prockop, DJ (2010). Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? Curr Opin Immunol 22: 768-774.
25. Siegel, G, Schafer, R and Dazzi, F (2009). The immunosuppressive properties of mesenchymal stem cells. Transplantation 87(9 Suppl): S45-S49.
26. Ren, G, Zhang, L, Zhao, X, Xu, G, Zhang, Y, Roberts, AI et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2: 141-150. (Pubitemid 351181031)
27. Rafei, M, Campeau, PM, Aguilar-Mahecha, A, Buchanan, M, Williams, P, Birman, E et al. (2009). Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-Dependent manner. J Immunol 182: 5994-6002.
28. Crop, M, Baan, C, Weimar, W and Hoogduijn, M (2009). Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl Int 22: 365-376.
29. Casiraghi, F, Azzollini, N, Cassis, P, Imberti, B, Morigi, M, Cugini, D et al. (2008). Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 181: 3933-3946.
30. Jarvinen, L, Badri, L, Wettlaufer, S, Ohtsuka, T, Standiford, TJ, Toews, GB et al. (2008). Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J Immunol 181: 4389-4396.
31. Sbano, P, Cuccia, A, Mazzanti, B, Urbani, S, Giusti, B, Lapini, I et al. (2008). Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res 300: 115-124.
32. Ding, Y, Bushell, A and Wood, KJ (2010). Mesenchymal stem-cell immunosuppressive capabilities: Therapeutic implications in islet transplantation. Transplantation 89: 270-273.